TY - JOUR
T1 - Modeling NK-cell lymphoma in mice reveals its cell-of-origin and microenvironmental changes and identifies therapeutic targets
AU - Koya, Junji
AU - Tanigawa, Tomohiko
AU - Mizuno, Kota
AU - Kim, Haryoon
AU - Ito, Yuta
AU - Yuasa, Mitsuhiro
AU - Yamaguchi, Kentaro
AU - Kogure, Yasunori
AU - Saito, Yuki
AU - Shingaki, Sumito
AU - Tabata, Mariko
AU - Murakami, Koichi
AU - Chiba, Kenichi
AU - Okada, Ai
AU - Shiraishi, Yuichi
AU - Marouf, Amira
AU - Liévin, Raphaël
AU - Chaubard, Sammara
AU - Jaccard, Arnaud
AU - Hermine, Olivier
AU - de Leval, Laurence
AU - Tournilhac, Olivier
AU - Damaj, Gandhi
AU - Gaulard, Philippe
AU - Couronné, Lucile
AU - Yasui, Teruhito
AU - Nakashima, Kazutaka
AU - Miyoshi, Hiroaki
AU - Ohshima, Koichi
AU - Kataoka, Keisuke
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein-Barr virus (EBV)-related neoplasm preferentially involving the upper aerodigestive tract. Here we show that NK-cell-specific Trp53 disruption in mice leads to the development of NK-cell lymphomas after long latency, which involve not only the hematopoietic system but also the salivary glands. Before tumor onset, Trp53 knockout causes extensive gene expression changes, resulting in immature NK-cell expansion, exclusively in the salivary glands. Both human and murine NK-cell lymphomas express tissue-resident markers, suggesting tissue-resident NK cells as their cell-of-origin. Murine NK-cell lymphomas show recurrent Myc amplifications and upregulation of MYC target gene signatures. EBV-encoded latent membrane protein 1 expression accelerates NK-cell lymphomagenesis and causes diverse microenvironmental changes, particularly myeloid propagation, through interferon-γ signaling. In turn, myeloid cells support tumor cells via CXCL16-CXCR6 signaling and its inhibition is effective against NK-cell tumors in vivo. Remarkably, KLRG1-expressing cells expand in the tumor and are capable of repopulating tumors in secondary recipients. Furthermore, targeting KLRG1 alone or combined with MYC inhibition using an eIF4 inhibitor is effective against NK-cell tumors. Therefore, our observations provide insights into the pathogenesis and highlight potential therapeutic targets, including CXCL16, KLRG1, and MYC, in ENKTCL, which can help improve its diagnostic and therapeutic strategies.
AB - Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein-Barr virus (EBV)-related neoplasm preferentially involving the upper aerodigestive tract. Here we show that NK-cell-specific Trp53 disruption in mice leads to the development of NK-cell lymphomas after long latency, which involve not only the hematopoietic system but also the salivary glands. Before tumor onset, Trp53 knockout causes extensive gene expression changes, resulting in immature NK-cell expansion, exclusively in the salivary glands. Both human and murine NK-cell lymphomas express tissue-resident markers, suggesting tissue-resident NK cells as their cell-of-origin. Murine NK-cell lymphomas show recurrent Myc amplifications and upregulation of MYC target gene signatures. EBV-encoded latent membrane protein 1 expression accelerates NK-cell lymphomagenesis and causes diverse microenvironmental changes, particularly myeloid propagation, through interferon-γ signaling. In turn, myeloid cells support tumor cells via CXCL16-CXCR6 signaling and its inhibition is effective against NK-cell tumors in vivo. Remarkably, KLRG1-expressing cells expand in the tumor and are capable of repopulating tumors in secondary recipients. Furthermore, targeting KLRG1 alone or combined with MYC inhibition using an eIF4 inhibitor is effective against NK-cell tumors. Therefore, our observations provide insights into the pathogenesis and highlight potential therapeutic targets, including CXCL16, KLRG1, and MYC, in ENKTCL, which can help improve its diagnostic and therapeutic strategies.
UR - https://www.scopus.com/pages/publications/85207178525
UR - https://www.scopus.com/inward/citedby.url?scp=85207178525&partnerID=8YFLogxK
U2 - 10.1038/s41467-024-53376-1
DO - 10.1038/s41467-024-53376-1
M3 - Article
C2 - 39438472
AN - SCOPUS:85207178525
SN - 2041-1723
VL - 15
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 9106
ER -